MedTrace Logo

LTFU Study of Subjects With Cervical SCI Who Received AST-OPC1

NCT05975424 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 25

Last updated 2024-08-21

No results posted yet for this study

Summary

This is a LTFU study for cervical SCI subjects that were administered AST-OPC1 cells in the main study AST-OPC1-01.

Conditions

  • Spinal Cord Injuries

Interventions

DIAGNOSTIC_TEST

Magnetic Resonance Imaging (MRI)

Observational study; annual MRI for first 5 years only to monitor changes in the injection site

Sponsors & Collaborators

  • Lineage Cell Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Gary Hogge, DVM, MS, PhD · Lineage Cell Therapeutics, Inc.

Eligibility

Min Age
18 Years
Max Age
69 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-13
Primary Completion
2033-01-14
Completion
2033-01-14
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05975424 on ClinicalTrials.gov